Consensus Allogene Therapeutics, Inc.

Stocks

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 16/10/2026 BST			5-day change	1st Jan Change
1.310 ^USD	-2.24%		-10.27%	-4.38%

09-14	Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company	MT
09-09	Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM

Evolution of the Average Target: Allogene Therapeutics, Inc.

Evolution of the Target Price: Allogene Therapeutics, Inc.

Changes in Analyst Recommendations: Allogene Therapeutics, Inc.

649ca09a8297a1.rUhILS-cA8d10QTtgCogX7pe8hGHuOLWTn8pqwKfUno.6w4gGWDLVbEsgjK09R9hHMgXvHC17Y-uBx5j-GWmFFfmMTtyF_0ugDShaw~81ab12490d22a4f3298af0a3d8f3081d

Analysts' recommendations: Allogene Therapeutics, Inc.

08-13	Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says	MT
04-16	JPMorgan Upgrades Allogene Therapeutics to Neutral From Underweight	MT
01-07	UBS Initiates Allogene Therapeutics at Buy With $8 Price Target	MT
10/10/25	JPMorgan Downgrades Allogene Therapeutics to Underweight From Neutral	MT
04/08/25	JPMorgan Downgrades Allogene Therapeutics to Neutral From Overweight	MT
07/07/25	RBC Cuts Price Target on Allogene Therapeutics to $9 From $10, Keeps Outperform, Speculative Risk	MT
14/05/25	Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating	MT
14/05/25	Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating	MT
08/11/24	Oppenheimer Adjusts Allogene Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	MT
08/08/24	Truist Adjusts Allogene Therapeutics' PT to $14 From $17, Keeps Buy Rating	MT
08/08/24	Oppenheimer Adjusts Allogene Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	MT
31/05/24	Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target	MT
21/05/24	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	MT
16/05/24	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating	MT
14/05/24	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating	MT
14/05/24	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating	MT
19/01/24	HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating	MT
05/01/24	B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating	MT
05/01/24	JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform	MT
08/12/23	Citigroup Starts Allogene Therapeutics With Buy Rating, $7 Price Target	MT
15/11/23	HC Wainwright Cuts Price Target on Allogene Therapeutics to $12 From $23, Keeps Buy Rating	MT
25/09/23	JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating	MT
11/07/23	Truist Securities Lowers Allogene Therapeutics' Price Target to $18 From $20, Maintains Buy Rating	MT
07/07/23	RBC Lowers Allogene Therapeutics' Price Target to $12 From $15, Keeps Outperform Rating	MT
05/05/23	JMP Securities Adjusts Allogene Therapeutics' Price Target to $15 From $19, Keeps Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALLOGENE THERAPEUTICS, INC.					+587.02%
	WUXI APPTEC CO., LTD.					+32.97%
	ARGENX SE					+38.45%
	LONZA GROUP AG					+14.74%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	BIONTECH SE					+33.01%
	Average					+84.42%
	Weighted average by Cap.					+28.89%